CSL Of Australia Accused Of Collusion By U.S. Regulator
This article was originally published in PharmAsia News
Executive Summary
Australia's CSL is being blocked in its attempt to buy U.S.-based Talecris Biotherapeutics Holdings in part because of alleged price manipulation in collusion with another company. The U.S. Federal Trade Commission has filed documents in court to back its case against allowing the CSL-Talecris merger. A U.S. district court judge issued a temporary restraining order against CSL's $3.1 billion acquisition of Talecris, a rival in the blood plasma market. According to the FTC filings, CSL and others have been under investigation for the past eight months as the agency probed irregularities. Among FTC allegations is collusion by many drug companies to monitor competitive information to help restrain output and keep prices up. CSL says it has not engaged in a conspiracy and that its prices are influenced by market factors. (Click here for more
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.